Cyclo Therapeutics, Inc. (CYTH)

Cyclo Therapeutics, Inc. (CYTH) Healthcare & Pipeline Overview

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company developing cyclodextrin-based therapies for rare and neurological diseases. Its primary focus is Trappsol Cyclo, an orphan drug in Phase III trials for Niemann-Pick Type C disease, with additional development for Alzheimer's. The company also generates revenue by selling cyclodextrins to various industries.

What Is the Investment Thesis for CYTH?

Cyclo Therapeutics, Inc. presents a research profile centered on its lead drug candidate, Trappsol Cyclo, a cyclodextrin-based product targeting Niemann-Pick Type C (NPC) disease. The drug's advancement into Phase III clinical trials for NPC, coupled with its orphan drug designation, represents a significant value driver, potentially offering market exclusivity upon approval. This designation is crucial given the rarity of NPC and the limited treatment options. Furthermore, the company's exploration of Trappsol Cyclo for Alzheimer's disease offers a substantial long-term growth catalyst, tapping into a much larger market if development progresses successfully. The existing revenue stream from selling cyclodextrins to various industries provides a foundational commercial base. However, as a clinical-stage biotechnology company, CYTH faces inherent risks, including the high failure rates associated with pharmaceutical development, potential regulatory hurdles, and its current negative profit margin of -1863.4%. The company's small scale, with 8 employees, underscores its reliance on the success of its lead pipeline asset. Investors would closely monitor clinical trial results, regulatory submissions, and the strategic management of its commercial segment to assess future prospects.

Based on FMP financials and quantitative analysis

CYTH Key Highlights

• Market Capitalization: $0.02 billion, reflecting its early-stage development and specialized focus within the biotechnology sector.
• Gross Margin: 90.9%, indicating strong profitability on its existing cyclodextrin product sales to various industries.
• Profit Margin: -1863.4%, characteristic of a clinical-stage biotechnology company with significant research and development expenses and limited commercial revenue.
• Lead Drug Candidate: Trappsol Cyclo is in Phase III clinical trials for Niemann-Pick Type C disease, representing a critical late-stage development milestone.
• Employee Count: 8 employees, highlighting a lean operational structure primarily focused on core research and development activities.

Who Are CYTH's Competitors?

CYTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CYTH's Key Strengths?

• Lead drug candidate, Trappsol Cyclo, holds Orphan Drug Designation for Niemann-Pick Type C disease, offering potential market exclusivity.
• Trappsol Cyclo is in advanced Phase III clinical trials for Niemann-Pick Type C, indicating significant progress in development.
• High Gross Margin of 90.9% on existing cyclodextrin product sales provides a strong base for commercial operations.
• Proprietary formulation of hydroxypropyl beta cyclodextrin represents specialized intellectual property.

What Are CYTH's Weaknesses?

• Currently a clinical-stage company with a negative Profit Margin of -1863.4%, reflecting high R&D costs and limited commercial revenue.
• Small operational scale with only 8 employees, potentially limiting capacity for broad pipeline development or extensive commercialization.
• High inherent risks associated with clinical-stage pharmaceutical development, including potential trial failures and regulatory hurdles.
• Significant dependence on the successful development and approval of a single lead drug candidate, Trappsol Cyclo.

What Could Drive CYTH Stock Higher?

• Announcement of top-line results from the Phase III clinical trial for Trappsol Cyclo in Niemann-Pick Type C disease.
• Submission of a New Drug Application (NDA) or Marketing Authorization Application (MAA) for Trappsol Cyclo in Niemann-Pick Type C disease to regulatory bodies.
• Initiation of later-stage clinical trials or significant data readouts for Trappsol Cyclo in Alzheimer's disease.
• Expansion of the commercial sales footprint for cyclodextrins and related products, contributing to revenue growth.

What Are the Key Risks for CYTH?

• Financial-distress signal — its Altman Z-Score of -45.56 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failure, particularly the ongoing Phase III trial for Trappsol Cyclo in Niemann-Pick Type C disease, which would significantly impact the company's prospects.
• Regulatory non-approval or delays in the review process for Trappsol Cyclo, which could postpone or prevent market entry.
• High operational costs and continued negative profit margins inherent to a clinical-stage biotechnology company, potentially requiring further capital raises.
• Intense competition in the Alzheimer's disease market from larger pharmaceutical companies with greater resources and established pipelines.
• Dependence on a single lead drug candidate, Trappsol Cyclo, making the company highly vulnerable to its success or failure.

What Are the Growth Opportunities for CYTH?

• Successful Commercialization of Trappsol Cyclo for Niemann-Pick Type C Disease: The primary growth driver for Cyclo Therapeutics is the successful completion of Phase III clinical trials and subsequent regulatory approval for Trappsol Cyclo in Niemann-Pick Type C (NPC) disease. As an orphan drug, Trappsol Cyclo would benefit from market exclusivity, typically for seven years in the U.S. and ten years in Europe, upon approval. The global market for Niemann-Pick disease treatments, while niche, represents a critical unmet need, with an estimated patient population that could generate significant revenue for a first-in-class or best-in-class therapy. Successful commercialization would transition the company from a clinical-stage entity to a revenue-generating pharmaceutical company, providing a stable foundation for future development.
• Advancement of Trappsol Cyclo for Alzheimer's Disease: The development of Trappsol Cyclo for Alzheimer's disease represents a substantial long-term growth opportunity. Alzheimer's disease affects millions globally, with a market size projected to reach hundreds of billions of dollars. While significantly more competitive than the NPC market, a successful therapeutic in this area could transform Cyclo Therapeutics' market valuation and revenue profile. The company's ongoing research in this area, though in earlier stages, positions it to potentially tap into one of the largest and most critical neurological disease markets, offering a diversified pipeline beyond rare diseases.
• Expansion of Cyclodextrin and Related Product Sales: Cyclo Therapeutics currently generates revenue from the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries for diagnostics and specialty drugs. This existing commercial segment provides a stable, albeit smaller, revenue base with a strong gross margin of 90.9%. Expanding the customer base, diversifying product offerings within the cyclodextrin market, or identifying new industrial applications could lead to incremental revenue growth. This segment offers a less volatile revenue stream compared to drug development and can help fund ongoing R&D efforts, reducing reliance on external capital.
• Leveraging Cyclodextrin Platform for New Indications: The company's expertise in cyclodextrin-based products suggests a platform technology that could be applied to other diseases beyond Niemann-Pick Type C and Alzheimer's. The broad utility of cyclodextrins in drug delivery and solubilization could enable Cyclo Therapeutics to explore and develop new drug candidates for other rare genetic disorders or neurological conditions where existing treatments are inadequate. Identifying and initiating preclinical or early-stage clinical programs for additional indications would diversify its pipeline and create new potential revenue streams in the medium to long term, capitalizing on its core scientific knowledge.
• Strategic Partnerships and Collaborations: As a small clinical-stage biotechnology company, forming strategic partnerships or collaborations with larger pharmaceutical companies could accelerate the development and commercialization of Trappsol Cyclo. Such partnerships could provide access to greater financial resources, extensive clinical development expertise, and established global commercialization infrastructure. A licensing agreement or co-development deal, particularly for the Alzheimer's program or for international markets for NPC, could significantly de-risk development, expand market reach, and provide substantial upfront payments or milestone revenues, driving significant value for Cyclo Therapeutics.

What Opportunities Does CYTH Have?

• Successful commercialization of Trappsol Cyclo for Niemann-Pick Type C disease, leveraging orphan drug exclusivity.
• Expansion into the large market for Alzheimer's disease treatment if Trappsol Cyclo development progresses successfully.
• Growth in sales of cyclodextrins and related products to pharmaceutical, nutritional, and other industries.
• Potential for strategic partnerships or collaborations to accelerate development and market access.

What Threats Does CYTH Face?

• Failure of Trappsol Cyclo in ongoing or future clinical trials, particularly the critical Phase III for Niemann-Pick Type C.
• Inability to secure regulatory approval for Trappsol Cyclo from health authorities.
• Intense competition from existing or emerging therapies for Niemann-Pick Type C or Alzheimer's disease.
• Significant capital requirements and potential dilution for future funding rounds necessary to sustain R&D.

What Are CYTH's Competitive Advantages?

• Orphan Drug Designation: Trappsol Cyclo's orphan drug status for Niemann-Pick Type C disease provides potential market exclusivity upon approval, limiting direct competition for a defined period.
• Proprietary Formulation: The company's focus on Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, represents a specific intellectual property and development expertise in this compound.
• Specialized Expertise: Deep knowledge and experience in cyclodextrin chemistry and its application in therapeutic development for rare and neurological diseases.
• Late-Stage Clinical Asset: Having a lead candidate in Phase III for a rare disease provides a significant head start over potential new entrants in that specific therapeutic area.

What Does CYTH Do?

Cyclo Therapeutics, Inc., incorporated in 1990 and headquartered in Gainesville, Florida, is a clinical-stage biotechnology company dedicated to the development of cyclodextrin-based products for the treatment of a range of diseases. Initially known as CTD Holdings, Inc., the company rebranded to Cyclo Therapeutics, Inc. in September 2019, signaling a sharpened focus on its therapeutic pipeline. The core of its development efforts revolves around its lead drug candidate, Trappsol Cyclo. This proprietary formulation of hydroxypropyl beta cyclodextrin has received orphan drug designation, underscoring its potential to address a significant unmet medical need for a rare condition. Trappsol Cyclo is currently in Phase III clinical trials for the treatment of Niemann-Pick Type C (NPC) disease, a rare, progressive, genetic disorder characterized by an inability to transport cholesterol and other fats within cells, leading to their accumulation in various tissues and organs, particularly the brain, liver, and spleen. The advancement of Trappsol Cyclo through this late-stage clinical development represents a critical milestone for the company. Beyond NPC, Cyclo Therapeutics is also exploring the therapeutic potential of Trappsol Cyclo for the treatment of Alzheimer's disease, a significantly larger and more prevalent neurological disorder, which could open up a vast market opportunity if successful. In addition to its drug development pipeline, the company maintains a commercial segment, selling cyclodextrins and related products. These products are supplied to pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. This commercial activity provides an existing revenue stream, complementing its long-term drug development initiatives. With a lean operational structure, managing 8 employees, Cyclo Therapeutics navigates the complex landscape of pharmaceutical development, aiming to bring novel cyclodextrin-based solutions to patients with debilitating conditions.

What Products and Services Does CYTH Offer?

• Develops cyclodextrin-based drug candidates for various rare and neurological diseases.
• Focuses on Trappsol Cyclo, its lead drug candidate, a proprietary formulation of hydroxypropyl beta cyclodextrin.
• Conducts Phase III clinical trials for Trappsol Cyclo to treat Niemann-Pick Type C disease, an orphan indication.
• Explores Trappsol Cyclo's therapeutic potential for treating Alzheimer's disease.
• Sells cyclodextrins and related products to pharmaceutical, nutritional, and other industries.
• Provides these products primarily for use in diagnostics and specialty drugs.
• Operates as a clinical-stage biotechnology company with a lean team of 8 employees.

How Does CYTH Make Money?

• Drug Development and Commercialization: Primary long-term revenue potential from the successful development, regulatory approval, and commercial sales of proprietary drug candidates like Trappsol Cyclo for Niemann-Pick Type C disease and Alzheimer's disease.
• Specialty Chemical Sales: Generates immediate revenue through the sale of cyclodextrins and related products to other companies in the pharmaceutical, nutritional, and industrial sectors for their own diagnostic and specialty drug applications.
• Orphan Drug Strategy: Leverages orphan drug designation for its lead candidate, which, if approved, provides market exclusivity and other incentives, aiming to capture a significant share of a niche market.

What Industry Does CYTH Operate In?

Cyclo Therapeutics, Inc. operates within the highly specialized and research-intensive Drug Manufacturers - Specialty & Generic industry, specifically focusing on rare diseases and neurological disorders. The company's strategic positioning targets unmet medical needs, particularly with its lead candidate, Trappsol Cyclo, for Niemann-Pick Type C disease. The broader pharmaceutical industry is characterized by significant R&D investment, long development timelines, and stringent regulatory pathways. Within this landscape, companies focusing on orphan drugs, like Cyclo Therapeutics, benefit from specific incentives such as extended market exclusivity and tax credits, designed to encourage development for rare conditions that might otherwise be overlooked due to small patient populations. The competitive landscape for rare diseases often involves a few specialized players, while the Alzheimer's market is highly competitive with numerous large pharmaceutical companies. Cyclo Therapeutics' approach leverages cyclodextrin-based technology, differentiating its product pipeline within these therapeutic areas.

Who Are CYTH's Key Customers?

• Patients suffering from Niemann-Pick Type C disease (potential future customers for Trappsol Cyclo).
• Patients with Alzheimer's disease (potential future customers for Trappsol Cyclo).
• Pharmaceutical companies utilizing cyclodextrins in their drug formulations.
• Nutritional companies incorporating cyclodextrins into their products.
• Other industrial clients requiring cyclodextrins for specialty applications and diagnostics.

Company Profile

Cyclo Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Gainesville, US. The company is led by CEO N. Scott Fine. CYTH has traded publicly since 2000.

How Cyclo Therapeutics, Inc. Is Valued

Cyclo Therapeutics, Inc. carries a market capitalization of $23.59M, placing it in the micro-cap category. Relative to its peer group, CYTH's quantitative score of 50/100 is below the peer average of 66/100.

Key Financial Metrics

Its free cash flow yield is -68.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -170.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Cyclo Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -45.56 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cyclo Therapeutics, Inc. revenue of about $28.5M for fiscal 2026, with EPS near $-0.13.

Net buyingInsider Activity

The most recent 12 insider filings for Cyclo Therapeutics, Inc. break down as 0 sales and 12 purchases. On net that is roughly 4.3M shares acquired (about $2.5M) — insiders putting money in tends to read as conviction.

CYTH Financials

CYTH Latest News

CYTH Analyst Consensus

CYTH MoonshotScore

Common Questions About CYTH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources